Abstract 2654
Background
Ewing sarcomas (ES) are malignant mesenchymal neoplasms composed of blue small round cells. Ewing sarcomas genetically are characterized mainly by the translocation t(11;22)(q24;q12), which creates EWS/FLI1 fusion gene. These translocations require Double Strand Break (DSB) formation and subsequent dysfunctional repair. BRCAness and HR deficiency have been reported in ES and clinical trials targeting DSB repair are currently ongoing.
Methods
We have studied the expression of Non-Homologous End Joining (NHEJ) and Homologous Recombination (HR) genes in 32 cases of Ewing sarcoma. Baseline clinicopathological characteristics were recorded from the medical files. The expression of the following genes XRCC4, XRCC5, XRCC6, Pol λ, Pol m, Lig4, RAD51, RAD52, RAD54, BRCA1, BRCA2, FRANCC, FRANCD, DNMT1 and BRIT1 was analyzed with Real-Time PCR. Samples from healthy blood donors were used as controls. Statistical analysis was performed using SPSS Anova.
Results
Nine genes out of the 15 studied showed statistically significant results. XRCC5, XRCC6, Polm, lig4 from the NHEJ DNA repair mechanism and RAD51, RAD52, RAD54, BRCA2 and FRANCD from the HR DNA repair mechanism were upregulated. Interestingly, several parts of both DSB repair mechanisms seem to be dysfunctional highlighting the involvement of NHEJ and HR in the oncogenesis of ES.
Conclusions
Genes involved both to NHEJ and HR show statistically important differences in their expression in Ewing sarcoma tumor samples. DSB repair mechanisms seem to be upregulated in a manner that supports the reported articles implying that it could be a potentially important target for new therapeutic approach to these lethal tumors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Hellenic Society of Medical Oncology.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1735 - mTOR inhibition in the treatment of resistant breast cancer
Presenter: María Rodriguez
Session: Poster Display session 1
Resources:
Abstract
6068 - Study of Photodynamic therapy in vitro
Presenter: Irene Jiménez Munguía
Session: Poster Display session 1
Resources:
Abstract
3011 - The potential of neratinib plus dasatinib in overcoming and preventing neratinib resistance in HER2-positive breast cancer models
Presenter: Neil Conlon
Session: Poster Display session 1
Resources:
Abstract
2644 - Novel HDACi, MHY446, induces apoptosis via regulation of mitochondria-endoplasmic reticulum interaction in HCT116 human colorectal cancer cells
Presenter: Nam Deuk Kim
Session: Poster Display session 1
Resources:
Abstract
3085 - Dual inhibition of TGF-β and AXL as a novel treatment for colorectal cancer
Presenter: Davide Ciardiello
Session: Poster Display session 1
Resources:
Abstract
1314 - PARP inhibition enhances cisplatin sensitivity in cervical cancer by modulating β-catenin signaling
Presenter: Minakshi Mann
Session: Poster Display session 1
Resources:
Abstract
2417 - Synergistic effect of DSF combined treatment with cisplatin in atypical teratoid/rhabdoid tumors (AT/RT)
Presenter: Seung Ah Choi
Session: Poster Display session 1
Resources:
Abstract
1149 - Reactive oxygen species induced by OSU-A9 inhibit the growth of duodenal cancer and gastric cancer cells through dephosphorylating intranuclear pyruvate kinase muscle isozyme M2
Presenter: Li-Yuan Bai
Session: Poster Display session 1
Resources:
Abstract
1862 - New therapy for intrahepatic cholangiocarcinoma targeted to cancer associated fibroblasts
Presenter: Takahiro Yamanaka
Session: Poster Display session 1
Resources:
Abstract
782 - Macrophage-cancer cell fusion is mediated by Phosphatidylserine-CD36 receptor interaction and induced by ionizing radiation
Presenter: Ivan Shabo
Session: Poster Display session 1
Resources:
Abstract